A case report of prenatal exposure to rosuvastatin and telmisartan.
Statins are considered to be a standard treatment for hyperlipidemia. Central nervous system, limb and midline defects have been reported in newborns exposed to statins in utero, although causality has been questioned. A 22-month-old boy with severe microcephaly, growth retardation, dysmorphic features, profound global developmental delay and peri-Sylvian polymicrogyria on brain imaging is presented. He was born to a mother exposed to telmisartan during the first seven months and rosuvastatin throughout the entire pregnancy. There were no features of fetopathy associated with sartans including telmisartan, such as a history of oligohydraminios and renal abnormalities. Given the increasing prevalence of obesity and its related complications (including dyslipidemias and hypertension) in young women of childbearing age, more safety data for prenatal exposure to statins and sartans are urgently needed.
Trakadis
Yannis
Y
Division of Clinical and Metabolic Genetics;
Blaser
Susan
S
Hahn
Cecil D
CD
Yoon
Grace
G
J Am Coll Cardiol. 2002 Aug 7;40(3):567-72
12142128
Ann Pharmacother. 2005 Jan;39(1):157-61
15590878
Annu Rev Genomics Hum Genet. 2001;2:299-341
11701653
Curr Top Dev Biol. 2003;53:1-114
12509125
Am J Med Genet A. 2004 Dec 15;131(3):287-98
15546153
Am J Med Genet A. 2005 Jun 1;135(2):230-1; author reply 232-4
15810007
Birth Defects Res A Clin Mol Teratol. 2005 Feb;73(2):123-30
15669052
Teratology. 1994 Dec;50(6):387-94
7778043
Early Hum Dev. 2005 Mar;81(3):245-53
15814206
Nat Neurosci. 2005 Apr;8(4):468-75
15793579
Arch Dis Child. 1998 Feb;78(2):185-9
9579167
Br J Clin Pharmacol. 2007 Oct;64(4):496-509
17506782